Latest News about INCY
Recent news which mentions INCY
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
From Benzinga
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
September 23, 2021
From Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
From Benzinga
10 Biggest Price Target Changes For Thursday
September 23, 2021
From Benzinga
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
September 22, 2021
Tickers
INCY
From Benzinga
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
September 22, 2021
From Motley Fool
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
From Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
September 22, 2021
Tickers
INCY
From Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
From Benzinga
Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
September 20, 2021
Tickers
INCY
From Benzinga
Is AbbVie a Bad News Buy?
September 19, 2021
From Motley Fool
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
From Benzinga
From Benzinga
From Benzinga
If you’ve got the stock market jitters, here are 20 companies in two defensive sectors
August 30, 2021
From MarketWatch
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
From Benzinga
From Benzinga
These 20 ‘left behind’ stocks among the S&P 500 are expected to rise up to 59% over 12 months
August 26, 2021
From MarketWatch
From Benzinga
From Benzinga
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
August 17, 2021
From Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
August 13, 2021
From Benzinga
From Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 10, 2021
From Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
From Benzinga
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
August 07, 2021
From Motley Fool
Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript
August 03, 2021
Tickers
INCY
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.